findmyKOL

Michael Salerno, MD, PhD

Basic profile

University of California, San Francisco

ORCIDNPI
RegionSan Francisco, CA · WestSpecialtyCardiovascular DiseaseFocusCardiology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH funding2022–2024Why? →

Michael Salerno is a Cardiology physician affiliated with University of California, San Francisco. OpenAlex indexes 399 publications with 12,993 citations (h-index 52).

Overview

Scholarship

indexed output and impact (OpenAlex)
399publications

Distinct works indexed by OpenAlex, matched via ORCID.

12,993citations

Total citations across indexed works.

52h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
10companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 2022–2024

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

505 Parnassus Ave # M-314
San Francisco, CA 941432204

Telephone

415-476-1000

Provider last certified this registry record 2 Dec 2024.

View the NPPES registry record

Industry payments

10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2022)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    72.3%
    Beta blocker48.9%
    Metoprolol Succinate100%
    Part D12 patients
    Angiotensin receptor blocker (ARB)23.4%
    Losartan Potassium100%
    Part D<11 patients
  • Blood & clotting

    27.7%
    Factor Xa inhibitor27.7%
    Eliquis100%
    Part D<11 patients
Where care is delivered (Part B)95.6% facility · 4.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 20222024 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”